Mitochondria as one of potential anticancer target, alternatively damaging mtDNA other than
nDNA is a potential method for platinum-based anticancer drugs to overcome cisplatin …

Given that currently used classical chemotherapeutic drugs lack the ideal therapeutic effect
and produce severe side effects, platinum nanomaterials (Pt-NMs) have gradually gained …

Despite the wide clinical use of platinum drugs in cancer treatment, their severe side effects
and lack of tumor selectivity seriously limit their further clinical application. To address the …

A novel class of platinum (IV) complexes comprising a monoaminophosphonate ester
moiety, which can not only act as a bone-targeting group but also inhibit matrix …

The use of cisplatin and its derivatives in cancer treatment triggered the interest in metal-
containing complexes as potential novel anticancer agents. Palladium (II)-based complexes …

Platinum-based anticancer drugs constitute the cornerstone of chemotherapy for various
cancers. Although cytotoxic agents are considered to have immunosuppressive effects …

The aim of this study was to compare anti-tumor potency of platinum (IV) complexes with
increasing hydrophobicity of their ligands. Cytotoxic potential of the new platinum (IV) …

Developing multifunctional platinum (IV) prodrugs via integrating bioactive pharmacophores
into one entity is an attractive strategy to ameliorate the defects of platinum (II) drugs. Herein …

Herein, ruthenium complexes containing heterocyclic thioamidates [Ru (mmi)(bipy)(dppb)]
PF6 (1),[Ru (tzdt)(bipy)(dppb)] PF6 (2),[Ru (dmp)(bipy)(dppb)] PF6 (3) and [Ru …

Although arsenic trioxide (ATO) shows a strong anti-tumor effect in the treatment of acute
promyelocytic leukemia, it does not benefit patients with hepatocellular carcinoma (HCC) …